These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29040252)

  • 1. In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
    Flaherty K
    Clin Adv Hematol Oncol; 2017 Oct; 15(10):745-747. PubMed ID: 29040252
    [No Abstract]   [Full Text] [Related]  

  • 2. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN
    Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of binimetinib for the treatment of melanoma.
    Specenier P
    Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
    Ngo P; Bycroft R
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of encorafenib for BRAF-mutated advanced melanoma.
    Koelblinger P; Thuerigen O; Dummer R
    Curr Opin Oncol; 2018 Mar; 30(2):125-133. PubMed ID: 29356698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encorafenib and Binimetinib: First Global Approvals.
    Shirley M
    Drugs; 2018 Aug; 78(12):1277-1284. PubMed ID: 30117021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
    Trojaniello C; Festino L; Vanella V; Ascierto PA
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].
    Di Guardo L
    Recenti Prog Med; 2022 Jun; 113(6):28e-30e. PubMed ID: 35758129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
    Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
    Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encorafenib, binimetinib and cetuximab combined therapy for patients with
    Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
    Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
    Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
    Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
    Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
    [No Abstract]   [Full Text] [Related]  

  • 16. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.
    Fujimura T; Yoshino K; Kato H; Fujisawa Y; Nakamura Y; Yamamoto Y; Kunimoto K; Ito T; Matsushita S; Maekawa T; Ohuchi K; Amagai R; Muto Y; Furudate S; Kambayashi Y; Hashimoto A; Aiba S
    J Dermatol; 2021 Mar; 48(3):397-400. PubMed ID: 33179310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
    Ascierto PA; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Quaglino P; Lebbé C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Gonzalez-Cao M; Minisini AM; De Placido S; Sanmamed MF; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Palmieri G; Dummer R; Sileni VC
    NEJM Evid; 2024 Oct; 3(10):EVIDoa2400087. PubMed ID: 39315864
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Imai T; Shoji H; Hirano H; Matsuguma K; Awatsu T; Hirose T; Okita N; Takashima A; Kato K
    CNS Oncol; 2024 Jun; 13(1):2347824. PubMed ID: 38869444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case of inflammatory arthritis induced by encorafenib and binimetinib in a patient with melanoma.
    Matsudate Y
    J Dermatol; 2020 Sep; 47(9):e328-e329. PubMed ID: 32613671
    [No Abstract]   [Full Text] [Related]  

  • 20. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
    Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
    Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.